Cargando…
All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy
Synergistic immunotherapy of immune checkpoint blockade (ICB) and immunogenic cell death (ICD) has shown remarkable therapeutic efficacy in various cancers. However, patients show low response rates and undesirable outcomes to these combination therapies owing to the recycling mechanism of programme...
Autores principales: | Song, Sukyung, Shim, Man Kyu, Yang, Suah, Lee, Jaewan, Yun, Wan Su, Cho, Hanhee, Moon, Yujeong, Min, Jin Young, Han, Eun Hee, Yoon, Hong Yeol, Kim, Kwangmeyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276196/ https://www.ncbi.nlm.nih.gov/pubmed/37334068 http://dx.doi.org/10.1016/j.bioactmat.2023.05.016 |
Ejemplares similares
-
Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
por: Cho, Hanhee, et al.
Publicado: (2021) -
Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
por: Moon, Yujeong, et al.
Publicado: (2022) -
Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses
por: Kim, Jeongrae, et al.
Publicado: (2022) -
Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death
por: Choi, Yongwhan, et al.
Publicado: (2020) -
In vivo toxicity evaluation of tumor targeted glycol chitosan nanoparticles in healthy mice: repeated high-dose of glycol chitosan nanoparticles potentially induce cardiotoxicity
por: Chang, Hyeyoun, et al.
Publicado: (2023)